Cancer Research

Colorectal cancer
#Artificial intelligence (AI) #Cancer Research Horizons #Colorectal cancer #Multi-omics #Oncology

Partners develop AI tools to personalise colon cancer treatment

Cancer Research Horizons has announced a collaboration with Histofy to develop tools that predict how colorectal cancer patients respond to different treatment options using the multi-modal S:CORT dataset.  As part of the collaboration, Histofy will use digital pathology images, as well as clinical and molecular data, from… Read More

#Business & Investment #Cancer Research #News

Blushwood tree
#Head and neck cancer #Oncology #Plant-based #QBiotics #Solid tumours #The Institute of Cancer Research

Could a molecule from a rainforest tree treat solid tumour cancers?

Scientists at The Institute of Cancer Research, London, are collaborating with life sciences company QBiotics to understand the molecular and cellular mechanisms of a potential new cancer drug.  The collaborative team will study the effects of tigilanol tiglate – a naturally occurring small molecule derived from the… Read More

#Cancer Research #Editor's Choice #News

X-ray showing colon cancer
#Bowel cancer #Cancer Research UK #Colorectal cancer #Oncology #Personalised medicine

CRUK commits £5.5m to transform bowel cancer treatment

Cancer Research UK and partners have committed £5.5 ($7.1) million in funding to form a world-leading research team tasked with making personalised medicine a reality for people with bowel cancer.  The CRC-STARS initiative will bring together over 40 research experts from across the UK, Spain, Italy and… Read More

#Cancer Research #News

Institute of Cancer Research
#ATR inhibitors #Genetics / genomics #Oncology #The Institute of Cancer Research

Genetic study predicts success of ATR inhibitors in rare cancer

Scientists at The Institute of Cancer Research, London, have identified a gene that affects how ovarian clear cell carcinoma (OCCC) could respond to a new class of drug called ATR inhibitors.  In clinical trials, ATR inhibitors have demonstrated efficacy as a treatment for various types of cancer,… Read More

#Cancer Research #Editor's Choice #News

Eye
#Cancer research #Eye health #iOnctura

Phase II study in metastatic uveal melanoma commences

iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, has dosed the first patient in the randomised Phase II OCULE-01 study investigating lead asset roginolisib in patients with metastatic uveal melanoma (UM), a rare cancer of the eye. Roginolisib is an orally dosed small molecule allosteric modulator of PI3Kδ. Read More

#Cancer Research #News

#Oncology #Peptides #Transcriptomics #University of Bath

Promising drug candidates for previously ‘undruggable’ target

Reportedly for the first time, researchers from the University of Bath have identified  promising  drug candidates that bind irreversibly with a notoriously ‘undruggable’ cancer protein target, permanently blocking it. Transcription factors are proteins that act as ‘master switches’ of gene activity and play a key role in cancer… Read More

#Cancer Research #News #Trending News

T cells attacking cancer
#Cell therapy #Haematology #Oncology #Orca Bio #Phase III trial

Allogeneic T-cell therapy doubles rate of survival free from GvHD

Biotechnology company Orca Bio has revealed positive results from the Phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with haematological malignancies.  The trial included patients with acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), high-risk myelodysplastic syndrome (MDS) and mixed-phenotype acute… Read More

#Cancer Research #News #Trending News

Cancer cells
#Cancer research #Cryoablation #Immunotherapy #Williams Cancer Institute

Beyond chemo: The shift toward multi-pronged cancer treatment

Dr Jason Williams, Founder and Director of Interventional Oncology and Immunotherapy at The Williams Cancer Institute, discusses leveraging immunotherapy and cryoablation for a new era in cancer treatment. The paradigm of cancer treatment is shifting. For decades, chemotherapy and radiation have been the pillars of oncology, but their limitations are… Read More

#Cancer Research #Exclusive Content

Cancer cells
#Japan #Oncology #Phase II trial #Rare cancers

Dual approach could transform treatment of rare cancer

Researchers have combined immunotherapy and chemotherapy to offer new hope for patients with thymic carcinoma, a rare and aggressive cancer.  Thymic carcinoma is often associated with poor prognosis in advanced or recurrent stages. However, its rarity has delayed the development of novel pharmacotherapy.   Now, researchers… Read More

#Cancer Research #News #Trending News

#Cancer research #Cancer therapeutics #Financing #Small molecules #Vivace Therapeutics

Financing secured for cancer drug targeting the Hippo pathway

Vivace Therapeutics has announced the closing of $35 million Series D financing to support the company’s small molecule cancer therapeutics targeting the Hippo pathway. The round was led by RA Capital Management, an existing investor, and included investment from other existing investors Canaan Partners and Cenova Capital. Proceeds will support… Read More

#Cancer Research #News

Acute lymphoblastic leukemia
#Bantam Pharmaceutical #Clinical trials #Health Canada #Lymphoma #Small molecules

Trial evaluating treatment for R/R mature B-cell lymphomas

Bantam Pharmaceutical, a company targeting selective modulation of mitochondrial dynamics in cancer, is proceeding with a Phase I clinical trial evaluating BTM-3566 in relapsed/refractory (R/R) mature B-cell lymphomas, based on a recent Clinical Trial Application (CTA) cleared by Health Canada. This regulatory milestone enables Bantam to expand its ongoing clinical… Read More

#Cancer Research #News

Ki67 staining
#Antibody drug conjugate (ADC) #Biospecimen collection #Monoclonal antibodies #Oncology

Advancing cancer therapy with antibody-drug conjugates

Cathie Miller, PhD, Senior Director of Product Marketing at BioIVT, discusses biospecimens and analytical techniques supporting the rapid evolution of ADCs in oncology. Antibody-drug conjugates (ADCs) are making significant strides forward as targeted cancer therapies. By coupling the specificity of antibodies with the potency of cytotoxic drugs, ADCs aim to… Read More

#Cancer Research #Exclusive Content

#Cancer Research UK #Gene mutation #Genetics / genomics #Oncology #Paediatrics #The Institute of Cancer Research

International team unlocks the genetic secrets of neuroblastoma

A team of international researchers have secured £1.5 ($1.9) million funding from Cancer Research UK (CRUK) to study the genetic secrets of childhood cancer neuroblastoma.  The project will be led by scientists at the University of Sheffield, alongside colleagues from The Institute of Cancer Research (ICR), Kings… Read More

#Cancer Research #News #Trending News

Pancreatic cancer
#Cancer drug targets #Gene mutation #Oncology #The Institute of Cancer Research

Algorithm identifies new potential targets for cancer drugs

Scientists have developed a tool which helps them better understand cancer’s survival tactics and could eventually lead to new treatments for dozens of cancers.  ‘Synthetic lethality’, the tactic of blocking pathways that cancer cells rely on, has so far mainly been successful in patients with BRCA-mutated breast,… Read More

#Cancer Research #News #Trending News